Clinical Trial Update: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for a vaccine against respiratory syncytial virus being tested in Chinese adults at increased risk, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV Vaccine (GSK)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: RECRUITING